Related Experiment Video
Updated: Dec 11, 2025
Validation of Therapeutic Agent Conjugation to Polyvinyl Alcohol-Coated Medical Devices
Published on: November 29, 2024
Experience With Teduglutide in Pediatric Short Bowel Syndrome: First Real-life Data
Esther Ramos Boluda1, Susana Redecillas Ferreiro2, Oscar Manrique Moral3
1Intestinal Rehabilitation Unit, Pediatric Gastroenterology and Nutrition Unit, University Hospital La Paz, Madrid.
Insights
Teduglutide treatment significantly reduced parenteral nutrition needs in pediatric patients with short bowel syndrome (SBS). Many achieved nutritional independence, demonstrating the drug
Area of Science:
- Gastroenterology
- Pediatric Medicine
- Clinical Pharmacology
Background:
- Short bowel syndrome (SBS) is a complex condition leading to intestinal failure.
- Parenteral nutrition (PN) is a common treatment for SBS, but carries risks.
- Teduglutide is a glucagon-like peptide-2 analog investigated for SBS treatment.
Purpose of the Study:
- To evaluate the real-world experience of teduglutide in Spanish pediatric patients with SBS.
- To assess the efficacy and safety of teduglutide in reducing PN dependency.
Main Methods:
- A cohort of 17 pediatric patients with SBS received subcutaneous teduglutide (0.05 mg/kg/day).
- Data collected included PN requirements, fecal losses, citrulline levels, and adverse events over 12 months.
- Demographic and clinical data were analyzed.
Main Results:
- 12 out of 17 patients achieved parenteral independence.
- Significant reductions in PN volume and caloric needs were observed.
- One patient discontinued treatment; two experienced adverse events (cholecystitis, cardiac decompensation).
Conclusions:
- Teduglutide is a safe and effective treatment for pediatric SBS, showing promising results in reducing PN dependence.
- Observed outcomes in this cohort surpassed those in pivotal trials and adult studies.
- Further research into long-term efficacy and safety is warranted.
Objectives:
The aim of the study was to describe the experience with teduglutide of several Spanish hospitals in pediatric patients with SBS (SBS).
Methods:
Seventeen pediatric patients with intestinal failure associated with SBS were treated with teduglutide. Patients received 0.05 mg · kg · day of subcutaneous teduglutide. Patients' demographics and changes in parenteral nutrition (PN) needs, fecal losses, and citrulline level initially and at 3, 6, and 12 months were collected, as well as any adverse events.
Results:
Patients were receiving 55 ml · kg · day and 33 kcal · kg · day of parenteral supplementation on average at baseline (2 patients received only hydroelectrolytic solution). A total of 12/17 patients achieved parenteral independence: 3 patients after 3 months of treatment, 4 patients at 6 months, and 5 after 12 months. One patient discontinued treatment 1 year after the beginning as no changes in parenteral support or fecal losses were obtained. All others decreased their intravenous requirements by 50%. One patient suffered an episode of cholecystitis, and another one with a pre-existing cardiac disease, developed a cardiac decompensation.
Conclusions:
Teduglutide seems to be a safe and effective treatment in the pediatric SBS population with better results than in the pivotal study as well as in the adult population.
Related Concept Videos
01:23Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption
01:30Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
01:17Drugs for Treatment of Diarrhea-Predominant IBS
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
01:21Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
01:17Pharmacokinetics in Pediatric Patients: Drug Distribution
01:26Pharmacokinetics in Pediatric Patients: Drug Excretion